Improving the life of patients with first-in-class radiopharmaceutical approaches
Compounds administered to more than 2,000 patients
CXCR4 compound extensively studied in 150+ scientific papers
Two Phase-III-ready drug candidates
Team of 80 employees with >80% R&D focus
